Veno-occlusive disease of the liver (VOD) is a common and severe complication of allogeneic hematopoietic stem cell transplantation (HSCT). To determine the incidence of, and the risk factors for the development of VOD, we performed a retrospective analysis of a series of 178 patients, who underwent allogeneic HSCT at our institution between 1990 and 1999. Busulfan and cyclophosphamide constituted the conditioning regimen most frequently administered. Bone marrow was the source of stem cells in 129 patients (73%), and peripheral blood (PBSC) in 49 patients (27%). Thirty-one patients of the PBSC group received CD34 + positively selected grafts. Most patients were given cyclosporin A and methotrexate (MTX) as graft-versus-host disease (GVHD) prophylaxis. Overall, 30 patients (17%) developed VOD. In univariate analyses, the incidence of VOD was significantly higher in recipients of unmanipulated grafts (20% vs 0%; P = 0.01), in patients with active malignant disease at transplantation (24% vs 9%; P = 0.03), in recipients of marrow from unrelated donors (33% vs 15%; P = 0.03), in patients grafted with bone marrow (21% vs 6%; P = 0.03), and in those receiving MTX as GVHD prophylaxis (21% vs 6%; P = 0.05). Under multivariate analysis, only CD34 + positive selection (P = 0.0004) and the status of the disease at transplant (P = 0.03) were statistically significant variables for the development of VOD. We conclude that CD34
transplantation (HSCT). [1] [2] [3] [4] [5] This syndrome is clinically characterized by jaundice, unexplained weight gain, ascites, and painful hepatomegaly, and results from extensive damage in zone 3 of the liver acinus. [1] [2] [3] [4] [5] The incidence of VOD varies widely between reports, ranging from 5% to 54%. 6, 7 This variation is probably a result of different criteria for the diagnosis of VOD, and the heterogeneous distribution of risk factors, as well as small sample sizes. The reported levels of associated mortality are also variable, and depend on the severity of VOD, reaching up to 90% in more severe cases. 6 Unfortunately, no effective measures are currently available for prophylaxis or treatment of VOD. Therefore, it is of interest to identify groups of patients at higher risk of developing VOD, to include them in well-designed and risk-adapted prophylactic and therapeutic trials. The intensity of conditioning regimen, age, Karnofsky score, previous level of transaminases, type of transplant (allogeneic vs autologous), previous abdominal radiation therapy and the use of estrogen-containing oral contraceptives in women, seem to be the most important predictive factors for the development of VOD. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the role of still other variables in VOD is unclear.
The main objectives of this study were to analyze the incidence, risk factors, and outcome of VOD in a series of 178 patients undergoing allogeneic HSCT, in a single institution. We report, for the first time, the independent prognostic value of CD34
+ -positive cell selection in the development of VOD.
Patients and methods

Patients
Between January 1990 and December 1999, 200 allogeneic HSCT were performed in our center. Twenty-two patients, undergoing unrelated cord blood cell transplants or second allogeneic HSCT, were excluded from the study. All the remaining 178 patients were considered eligible. There were 102 males and 76 females. The median age was 31 years (range, 14-60 years). Diagnoses included 44 cases of chronic myelogenous leukemia (CML), 60 acute myelogenous leukemia (AML), 25 acute lymphoblastic leukemia (ALL), 10 myelodysplastic syndrome (MDS), six non-Hodgkin's lymphoma (NHL), nine multiple myeloma (MM), four chronic lymphocytic leukemia (CLL), 12 aplastic anemia (AA), and eight other diagnoses (nocturnal paroxysmal hemoglobinuria, myelofibrosis, and congenital erythroid disorders). In 147 cases (83%), the donor was an HLA-identical sibling; in 19 cases (10%), an HLA-identical unrelated donor; and in 12 cases, a partially HLAmismatched donor (10 from a relative, and two from an unrelated donor).
Conditioning
One hundred and three patients received BuCy2 as the conditioning regimen, consisting of busulfan (Bu) given orally at a dose of 4 mg/kg/day, in four divided doses each day for 4 days (total dose, 16 mg/kg), followed by cyclophosphamide (Cy) administered intravenously over 1 h, at a daily dose of 60 mg/kg for 2 days (total dose, 120 mg/kg). Twenty-three patients received combinations of BuCy2 with VP16, thiotepa and/or antithymocyte globulin (ATG). 
Graft-versus-host disease (GVHD) prophylaxis
One hundred and thirty-one patients (74%) were administered cyclosporin A (CsA), plus a short course of methotrexate (MTX); 46 patients (26%) received CsA plus prednisone; and the remaining patient received CsA alone.
Source of stem cells
One hundred and twenty-nine patients (73%) received unmanipulated bone marrow grafts, and 49 patients (27%) received peripheral blood stem cell (PBSC) grafts. Thirtyone patients, in the PBSC group, received CD34 + positively selected grafts, whereas 18 received unmanipulated grafts. CD34
+ cell selection was performed using biotin-avidin immunoadsorption 12 (Ceprate SC; CellPro, Bothell, WA, USA) in 23 patients, and immunomagnetic-activated cell sorting in eight patients (CliniMACS; Miltenyi Biotech, Bergisch-Gladbach, Germany). 5 VOD is defined as the presence of a serum bilirubin level greater than 2 mg/dl within 30 days after HSCT, together with two of the following criteria: weight gain greater than 5% of basal, ascites, or painful hepatomegaly. VOD was classified according to McDonald et al 6 as mild if it resolved before day 100 without treatment; moderate, when resolved before day 100, but the patient has received treatment for VOD; and severe when it did not resolve before day 100.
Diagnosis of VOD
According to Jones et al
Variables and definitions
The following variables were analyzed for their association with the development of VOD: age, sex, diagnosis, disease stage and disease status at transplant, serum transaminase enzymes (AST) levels before conditioning, active infection within 1 week before transplant, Karnofsky score, conditioning regimen, use of ATG, type of donor (related or unrelated), stem cell source, GVHD prophylaxis, and the use of positively selected CD34 + cells. According to McDonald et al, 4 the conditioning regimen is considered 'high dose' when it includes at least Bu plus Cy, or Cy plus TBI at a total dose of 12 Gy. All remaining regimens were considered 'low dose'. Patients with hematological malignancies in first complete remission (CR), or CML in first chronic phase (CP), were classified as having early disease stages, and the remaining conditions were classified as advanced disease stages. On the other hand, the disease status was classified as non-active malignant disease in patients in CR with acute leukemia (AL), MDS, NHL, and MM. The remaining patients with malignant diseases, including CML in CP, were classified as having active malignant disease. All other patients were classified with non-malignant disease. By diagnosis, the patients were classified into four groups: (1) CML; (2) AL and MDS; (3) MM and lymphoproliferative syndromes, including NHL and CLL; and (4) other diagnoses.
Statistical methods
Chi-square and Fisher's exact tests were used to analyze the association between VOD and the aforementioned variables. Multivariate analysis was performed by multiple logistic regression, using forward stepwise variable selection. 13 Variables selected for inclusion in the multivariate analysis were those for which there was some indication of a significant association with VOD development in univariate analyses (P Ͻ 0.10), or where prior studies had suggested a possible relationship. Computations were performed using 4F and LR programs from the BMDP statistical library (BMDP Statistical Software, Los Angeles, CA, USA).
Results
Incidence and characteristics of VOD
Overall, 30 of the 178 patients (17%) developed VOD. Characteristics of VOD are shown in Table 1 . All patients with VOD had a serum bilirubin level of more than 2 mg/dl, 17 (57%) had two of the three other features of VOD, and 13 (43%) had the three other features of VOD. The median time to onset was 12 days (range, 1-28 days). The median peak bilirubin level was 10.4 mg/dl (range, 3-54.9 mg/dl), which was observed at a median of 21 days after HSCT (range, 7-51 days). Seventeen patients were classified as having mild or moderate VOD (57%), and 13 as having severe VOD (43%). Sixteen patients (53%) in the VOD group died before day 100, compared with 30 (20%) in the group without VOD (P = 0.0006). The actuarial probability of death at day 100 in the group of patients with VOD was 53%, compared with 19% in patients without VOD (P Ͻ 0.0001). All patients with severe VOD, but only three with mild or moderate VOD, died before day 100 after HSCT.
Risk factors for VOD
The results of univariate analysis of risk factors for VOD are shown in Table 2 . VOD was significantly more frequent in recipients of unmanipulated grafts (P = 0.01); in patients with active malignant disease status at transplant (P = 0.03); in HSCT from unrelated donors (P = 0.03); in recipients for whom bone marrow was the source of progenitor cells (P = 0.03); and in those receiving MTX for GVHD prophylaxis (P = 0.05). There were no cases of VOD among the 31 recipients of CD34 + positively selected PBSC grafts, whereas the incidence of VOD was 17% (three of 18 cases) in recipients of unmanipulated PBSC grafts, and 21% (27 of 129 cases) in those receiving unmanipulated bone marrow.
Multivariate analysis showed that positive selection of CD34 + cells (P = 0.0004) and disease status at transplantation (P = 0.03) were the only independent risk factors for the development of VOD.
In order to avoid the heterogeneity in the distribution of several factors, such as GVHD prophylaxis, the type of donor or the source of stem cells, we performed a separate analysis of only PBSC recipients. In this setting, the incidence of VOD was significantly higher in transplants without CD34
+ selection (17% vs 0%; P = 0.04) and in patients with Karnofsky scores less than 90 (29% vs 2%; P = 0.05). In multivariate analysis, CD34
+ selection was the only significant variable related to the development of VOD (P = 0.01).
Characteristics of groups according to CD34
+ selection
The main characteristics of the groups of patients, with or without positively selected CD34 + grafts, are shown in Table 3 . The type of donor (P = 0.05), GVHD prophylaxis (P = 0.0001), and the source of the hematopoietic stem cells (P Ͻ 0.0001), differed significantly between the two groups. Each group of patients also showed a different disBone Marrow Transplantation tribution of disease stages. The remaining variables with a potential role in the development of VOD did not show any clear differences between these two groups.
Discussion
This study shows for the first time a strong relationship between the use of positive immunoselection of CD34 + cells from peripheral blood and the risk of VOD after allogeneic HSCT. No cases of VOD occurred among the patients who received PBSC transplants that were positively selected for CD34
+ , whereas the incidence of VOD in those patients receiving unmanipulated grafts, from bone marrow or peripheral blood, was within the range usually reported in most other large series. [4] [5] [6] [7] [8] [9] [10] The absence of VOD after CD34
+ selection in our series may have been due to several factors. Firstly, immunoselection of CD34 + cells for transplantation implies, per se, a partial T cell depletion. Soiffer et al 14 have previously reported a very low rate of VOD (3%) among 97 patients undergoing T cell-depleted allogeneic bone marrow transplantation. Although the mechanisms underlying the beneficial effect of T cell depletion on the risk of VOD are unknown, one hypothesis is that the reduced alloreactivity between donor and host after T cell depletion results in less endothelial damage to the hepatic veins and sinusoids. This damage is considered to be one of the earliest events in the pathogenesis of VOD after HSCT. 1 Activation of alloreactive T cells could lead to a liberation of some cytokines, which have been associated with the development of VOD. [15] [16] [17] In fact, increased levels of TNF-alpha are related to major complications of HSCT, including VOD. 15 Likewise, peripheral blood mononuclear cell TNF-alpha mRNA expression has been found preceding the onset of VOD, suggesting that an increase in TNF-alpha levels could be a cause of damage to small hepatic venules. 16 Similar results have been reported with IL-1-beta mRNA expression. 17 On the other hand, strong supportive evidence for the role of immunological phenomena in the emergence of VOD comes from a recent report of a clearly significant association between VOD and acute rejection after orthotopic liver transplantation. 18 The greater incidence of VOD after HSCT from unrelated donors noted in some series 6 could also be due to the higher alloreactivity between donor and recipient that exists in this setting. In the present series, the highest incidence of VOD also occurred in recipients of bone marrow from unrelated donors. Given the non-randomized retrospective nature of the study, the groups of patients with or without CD34
+ cellselected grafts could not be controlled for potential risk factors of VOD. Effectively, in recipients of CD34 + cell selected grafts, the source of cells was always peripheral blood, the transplant was from a family donor, and only one of the patients received MTX for GVHD prophylaxis. The previously reported role of these variables, mainly the source of stem cells and the GVHD prophylaxis, in the development of VOD, is unclear. In fact, information is lacking on the possible role of the source of stem cells, either bone marrow or peripheral blood, in the risk of VOD after allogeneic HSCT. [19] [20] [21] [22] [23] [24] Only in the autologous setting, one study has reported a lower incidence of VOD after transplantation with both bone marrow and peripheral blood stem cells than after transplantation with bone marrow stem cells alone. 25 On the other hand, although the use of MTX for GVHD prophylaxis has emerged as a potential risk factor for VOD in one series, 26 several large studies have failed to show any association. [4] [5] [6] However, all these variables were associated with the risk of VOD by univariate analysis in our series and they had a heterogeneous distribution. In order to avoid this heterogeneity we performed a separate analysis in the subset of PBSC recipients, and the CD34 + selection emerged in multivariate analysis as the only significant variable associated with the development of VOD (P = 0.01).
The impact of disease status at transplantation on the risk of VOD is far from clear. 5, 6, 8, 9 In this study, disease status was an independent predictive factor for the development of VOD after allogeneic transplantation. The prognostic weight of disease status also remained after excluding the patients with CD34
+ cell-selected grafts. Interestingly, the incidence of VOD was markedly higher in those patients with active malignant diseases, and was very similar among patients with inactive malignant diseases and non-malignant conditions. The procoagulant state present in active malignancies, that has also been observed in VOD, [27] [28] [29] [30] [31] and the much higher tumor load, could possibly explain the apparent role of disease status in the risk of VOD.
To sum up, our study strongly suggests that the use of positively selected CD34
+ cells results in a remarkable reduction in the risk of VOD after allogeneic HSCT. Partial T cell depletion, implicitly associated with immunoselection of CD34 + cells, is probably the main factor contributing to this effect, by diminishing alloreactivity. Given the clinical implications, prospective randomized studies are clearly required to confirm these results.
